Back to top
more

Patterson Companies (PDCO)

(Delayed Data from NSDQ)

$20.27 USD

20.27
689,626

-0.01 (-0.05%)

Updated Oct 8, 2024 03:59 PM ET

After-Market: $20.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (176 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

McKesson (MCK) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 9.79% and 5.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Despite Fast-paced Momentum, Patterson Cos. (PDCO) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Patterson Cos. (PDCO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Patterson Cos. (PDCO) Could Beat Earnings Estimates Again

by Zacks Equity Research

Patterson Cos. (PDCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Industry Outlook Highlights Becton, Dickinson and Company, Patterson Companies and SmileDirectClub

by Zacks Equity Research

Becton, Dickinson and Company, Patterson Companies and SmileDirectClub are part of Zacks Industry Outlook article.

3 Dental Supplies Stocks to Buy Amid Industry Headwinds

by Zacks Equity Research

Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, PDCO and SDC.

Patterson Cos. (PDCO) Up 2.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Best Income Stocks to Buy for July 25th

by Zacks Equity Research

WSBC, PDCO, and FNB made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 25, 2022.

Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.

Here's Why You Should Hold On to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day.

LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

by Zacks Equity Research

LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

PDCO or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. CNMD: Which Stock Is the Better Value Option?

QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome

by Zacks Equity Research

QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Potential to Fight Recession Risk

by Indrajit Bandyopadhyay

The decline in U.S. GDP during the first quarter and 26% decline in the S&P 500 Index so far this year fuel the risk of a recession. MCK, PDCO & AMN have the potential to help investors ward off volatility risks going forward.

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing

by Zacks Equity Research

NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care.

Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Alcon's (ALC) Product Launches, Market Recovery Aid Growth

by Zacks Equity Research

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

3 Reasons Why BD (BDX) is a Great Pick For Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Here's Why Investors Should Retain Phibro (PAHC) For Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.

LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis

by Zacks Equity Research

LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.

Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Fresenius (FMS) Faces Fraud Accusation From US Government

by Zacks Equity Research

The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.